MRK Research Update — September 18, 2026
Updated Thesis
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely high-margin branded-drug portfolio, but TTM net margin of just 4.8% and a trailing P/E of 114.66 show how heavily acquisition charges and earnings volatility are weighing on reported profitability.
The investment grade as of this refresh is C — average business quality. Medium-tier business, expensive-tier valuation with 4.1% downside to $141.07 fair value.
Key Metrics at a Glance
- Revenue growth: +5.1% year over year
- Net margin: 4.8%
- Fair value upside: -4.1% to our estimate of $141
Current price: $147.17
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Merck & Co., Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MRK research →](/stocks/MRK)